High-throughput, "next-generation" sequencing methods are now being broadly applied across all fields of biomedical research, including respiratory disease, critical care, and sleep medicine. Although there are numerous review articles and best practice guidelines related to sequencing methods and data analysis, there are fewer resources summarizing issues related to study design and interpretation, especially as applied to common, complex, nonmalignant diseases. To address these gaps, a single-day workshop was held at the American Thoracic Society meeting in May 2017, led by the American Thoracic Society Section on Genetics and Genomics. The aim of this workshop was to review the design, analysis, interpretation, and functional follow-up of highthroughput sequencing studies in respiratory, critical care, and sleep medicine research. This workshop brought together experts in multiple fields, including genetic epidemiology, biobanking, bioinformatics, and research ethics, along with physician-scientists with expertise in a range of relevant diseases. The workshop focused on application of DNA and RNA sequencing research in common chronic diseases and did not cover sequencing studies in lung cancer, monogenic diseases (e.g., cystic fibrosis), or microbiome sequencing. Participants reviewed and discussed study design, data analysis and presentation, interpretation, functional follow-up, and reporting of results. This report summarizes the main conclusions of the workshop, specifically addressing the application of these methods in respiratory, critical care, and sleep medicine research. This workshop report may serve as a resource for our research community as well as for journal editors and reviewers of sequencing-based manuscript submissions in our research field.
Overview
High-throughput, next-generation sequencing (NGS) technologies (see Box 1 for a glossary of terms) are becoming increasingly used in studies of common, complex diseases, including respiratory diseases such as asthma, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis; critical illnesses; and sleep disorders (Table 1, Figure 1 ) (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . RNA sequencing is now more cost effective than microarrays, and exome and wholegenome DNA sequencing are rapidly replacing genotyping arrays. Given the widespread application of these techniques in respiratory, critical care, and sleep medicine research, a workshop was organized at the ATS International Conference in Washington, DC in May 2017. The aim of this workshop was to review the design, analysis, interpretation, and functional follow-up of highthroughput sequencing studies in respiratory, critical care, and sleep medicine research. Although reviews and bestpractices guidelines for DNA and RNA sequencing have been published (16, 17) , this workshop focused on the application of DNA and RNA sequencing to common, complex diseases in human populations but not on epigenome or microbiome studies or cancer genetics.
Workshop Agenda
The workshop participants focused on five topics, each of which concluded with a panel discussion. Areas of emphasis included study design, ethical considerations and health inequalities, applications of DNA and RNA sequencing, cell type heterogeneity, and functional studies. Biomedical literature searches were conducted by the speakers and co-chairs. The co-chairs collected summaries from speakers, and a writing group prepared the document for review by the workshop participants. Recommendations were formulated by discussion and consensus (Box 2, Figure 2 ).
Principles of Study Design Study Designs and Phenotyping for Genetic Epidemiology
The general principles of epidemiology study design remain true for genetic epidemiology studies, including subject ascertainment, phenotype definition, and sample size considerations, as summarized in the Strengthening the Reporting of Genetic Association Studies (STREGA) Guidelines (18) . There are several possible designs for genetics studies of respiratory disease. In the past, most studies enrolled subjects ascertained for a specific condition. These studies usually use careful phenotyping to define the disease of interest using endotypes, such as methacholine challenge testing or polysomnography (19) (20) (21) . General population (cohort) studies may offer the advantage of large sample sizes and the ability to study multiple outcomes, although the phenotyping may not be as precise. Questionnaires may be the primary source of respiratory disease diagnosis,
Box 1. Definitions of Commonly Used Terms in Sequencing Studies
Batch effect: In a large study, library construction and sequencing is done in batches (e.g., 96-well plate), which is a source of technical variation that should be addressed in the data analysis.
although several large cohorts have included spirometry (22, 23) . For common diseases, the large numbers may offset the potential for phenotypic heterogeneity (e.g., childhood vs. adult-onset asthma) or even misclassification (e.g., chronic obstructive pulmonary disease [COPD] misdiagnosed as asthma, especially in women) (24) . Recent studies have linked genetics to the electronic medical record (25) . General population cohorts have limited utility in studies of critical illness, where subjects are enrolled in the hospital (26) . Although most recent studies have been case-control or cohort studies, family-based studies still play a role, especially in the analysis of rare variants, where transmission can be followed through a pedigree (27) .
As genomic data sharing has become the norm, secondary analysis for respiratory diseases is now routinely performed in general population studies, such as the Framingham Heart Study (22) . When secondary data will be used or when multiple studies will be combined in a meta-analysis, investigators must carefully review the phenotyping methods, including Definition of abbreviations: BPD = bronchopulmonary dysplasia; COPD = chronic obstructive pulmonary disease; DE = differentially expressed; FACS = fluorescence-activated cell sorter; IPF = idiopathic pulmonary fibrosis; KCO = carbon monoxide transfer coefficient; lncRNA = long noncoding RNA; PAH = pulmonary arterial hypertension; PCH = pulmonary capillary hemangiomatosis; PMVEC = pulmonary microvascular endothelial cells, PVOD = pulmonary veno-occlusive disease; qPCR = quantitative polymerase chain reaction; SIRS = Systemic Inflammatory Response Syndrome; SNP = single-nucleotide polymorphism; WGS = whole-genome sequencing.
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the specific questionnaire items, to be sure that similar traits are being compared. In case-control studies, control subjects should have comparable exposures, such as smokers with normal lung function in COPD studies or patients with multitrauma, pneumonia, or sepsis who did not develop acute respiratory distress syndrome (28) (29) (30) .
Biobanks
Sequencing studies undertaken at the scale required for well-powered association testing require organized efforts, with coordinated biobanking. Rare diseases and phenotypes may be due to genetic variants with high penetrance, which may be detectable in relatively modest numbers of samples. Even in this situation, and in the absence of many different mutations causing similar phenotypes, it is helpful to draw on very large numbers of sequenced individuals. Genomics England (the "100,000 Genomes Project") (31), the U.S. National Heart, Lung, and Blood Institute Trans-Omics in Precision Medicine (TOPMed) (32) , and the Genome Aggregation Database (33) are initiatives that will enhance such comparisons, which are critical to confirm whether variants are causal for the disease in question ( Table 2 ). The Genomics England project is recruiting patients with cancers, infectious diseases such as tuberculosis, and rare diseases, including primary ciliary dyskinesia, spontaneous pneumothorax, familial pulmonary fibrosis, and familial multiple pulmonary arteriovenous malformations.
Complementing efforts that specifically recruit individuals with particular diseases are population biobanks that are agnostic to health status, many of which have extensive longitudinal follow-up. The UK Biobank recruited 500,000 participants aged 40 to 69 years (34) . In addition to a baseline assessment, subsequent health status is evaluated via linked electronic healthcare records. Beginning with respiratory studies in 50,000 participants (35) , genome-wide genotyping has now been extended to all participants. Whole-exome sequencing (WES) is underway, and whole-genome sequencing (WGS) has recently been announced in collaboration with industry partners. The sequence data will be made available to the research community. Although 95% of the UK Biobank is of European ancestry, similar efforts are in progress in China in the Kadoorie Biobank (36) .
Health Equity
Many respiratory, critical care, and sleep disorders have substantial differences in disease susceptibility, prevalence, and burden according to race and ethnicity (37) . Genetic and genomic factors, along with their interplay with the environment, contribute to these differences. For example, African ancestry is a strong predictor of lung 
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function (38) . Some disease susceptibility or pharmacogenetic variants that have been identified in diseases such as asthma, emphysema, and sleep apnea (39) (40) (41) are population specific and may be absent or low frequency in other populations (42, 43) . Although most of these studies have been performed using common variants, there is even more ethnic diversity for rare variants (44) . Individuals of African ancestry harbor a larger number of rare variants than white individuals, which may have important clinical implications. For example, rare variants identified as causing cardiomyopathy in white individuals were so common in African Americans as to indicate that they were unlikely to be pathogenic (45) . To date, there has been a large gap in research studies involving non-white individuals, for reasons including convenience, access, and genetic heterogeneity (46) . In addition, there have also been disparities in funding minority investigators or diseases that predominately affect minorities, such as sickle cell disease (47) . By 2060, only 44% of the United States will be non-Hispanic white (48) . There is a strong scientific and moral justification for expanding sequencing studies into other ancestries. Efforts such as TOPMed are performing WGS in a large number of non-European samples. These and other efforts can help ensure that sequencing efforts improve health equity for the benefit of all.
Research Ethics
Several ethical challenges have emerged related to NGS studies. Because of the ability to assay numerous sites and the requirements for data sharing by the U.S. National Institutes of Health (NIH) and other funders (49), genome-wide association studies and sequencing data are often used for secondary studies, which may be unrelated to the initial trait or disease proposed. To allow for these studies, investigators must request and subjects must provide broad consent for secondary data analysis, as opposed to narrow consent for a specific disease. There is no consensus about what is required for broad consent for databases such as the National Center for Biotechnology Information database of Genotypes and Phenotypes (dbGaP) (50); these decisions are frequently left to local institutional review boards. In addition to the genes of interest, WES and WGS studies will identify other genetic variants that may be clinically significant for the subject or their family members. The American College of Medical Genetics has provided recommendations for the reporting of secondary results from clinical sequencing (51), providing a list of 59 actionable genes, which, interestingly, does not include the genes for cystic fibrosis or alpha-1 antitrypsin deficiency. However, it is not clear how these recommendations would apply to research studies, where the sequencing is not performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory. There is usually no mechanism or resources for confirmatory clinical sequencing or genetic counseling. Sequencing studies of DNA of patients with a critical illness require consent from patient proxies as well as the designation of an individual to receive study results if the patient remains incapacitated or dies (52).
Next-Generation DNA Sequencing Study Design
Humans carry an extraordinary amount of genetic diversity. Although most variants in a given individual are common, most genetic variants in a population are rare (i.e., present in ,1% of the population). 
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Genotyping microarrays, together with methods of genotype imputation, efficiently allow testing of more prevalent genetic variants. However, comprehensive assessment of DNA variation, including discovery of rare or novel variants, requires a test that assays each base pair. The exponential decrease in sequencing costs has led to the ability to perform WGS studies to identify the contributions of rare variants to disease.
The design of a DNA sequencing study should consider several factors. Sequencing depth determines the accuracy of variant calling in an individual. For example, 303 coverage leads to high accuracy over most of the genome. However, one can sequence more samples for the same cost using lower coverage (e.g., . Although less accurate, lower coverage still provides suitable variant information for genetic association testing and may be superior to genotyping (53) . Another consideration is targeted (e.g., exome) versus WGS. The exome harbors most rare, highly deleterious mutations; sequencing only these regions reduces costs, although these savings are offset somewhat by the additional costs and inefficiencies of library preparation. Some coding regions may still be poorly covered by WES (54) .
Identifying Causal Variants
NGS has led to breakthroughs in the discovery of genes for Mendelian diseases and other rare variants of strong effect (55, 56) . Several groups have provided guidelines for identifying causal variants for Mendelian disease (57) and for identifying genetic association in WES (58) and WGS (59) . However, the interpretation of WES and WGS data has specific challenges. Very small error rates over billions of base pairs have the potential to generate many false positives (60), although advances in technology, approaches, and bioinformatics methods have vastly improved data quality. Similarly, the large number of variants carried by any individual (27) can also lead to false positives, and caution must be used to avoid inflated estimates of pathogenicity (61) . In addition, most studies of rare variants are likely underpowered (5, 58, 62) . The growing availability of populationspecific high-quality reference genomes will aid comparison of diseased study populations to these reference datasets. Coordinated efforts are providing population-based reference data important for filtering causal variants (33) and performing WGS in large numbers of subjects, such as the NIH Centers for Common Disease Genomics and TOPMed. These efforts will lead to new rare variant discoveries as well as improved reference panels for genotyping studies and fine mapping. Table 3 details recommendations for reporting the results of a WES or WGS study.
Next-Generation RNA Sequencing Study Design
In contrast to genome sequence, gene expression is dependent on cell, tissue, and disease state. Although this context dependence makes sample collection and assays more challenging, gene expression may be more closely reflective of disease pathophysiology. Gene expression microarrays have been largely replaced by RNA-seq, which can assay a broader range of RNA types with increased sensitivity and lower costs. RNA-seq studies can be grouped into two broad categories on the basis of their study designs (63) . Annotation studies aim to define the transcriptome of a specific cell type or organism, including novel transcripts. In comparison, quantification or differential expression studies compare transcript levels across experimental conditions or diseases. An introduction to RNA-seq for bench science has been recently published (64) .
Several factors are important in designing an RNA-seq study in human populations. Because sequencing costs depend on the number of reads, there is an inherent trade-off between sample size and sequencing depth, similar to DNA sequencing. As low as 1 to 10 million reads per sample may be adequate for differential expression (65, 66) , whereas up to 200 million reads may be required to define all isoforms (67, 68) . For most human disease studies, the number of samples may be more important than the number of reads (69) .
Sequencing Methods
Sequencing technology has been reviewed elsewhere (70, 71) . Library construction follows one of three general protocols (72) . Poly-A capture is best for selecting coding transcripts but requires the highest-quality input RNA. Total RNA libraries include more RNA species; ribosomal RNA depletion is used to improve yield. Methods to capture specific target sequences can be used for lower-quality or fragmented RNA, including formalin-fixed paraffin-embedded tissue. Globin depletion is a common step for whole blood samples. Small RNA sequencing (i.e., microRNA) requires a specific library construction protocol.
Investigators must determine the minimum quality for input RNA, on the basis of RNA integrity number. Other (74) . The latter can be addressed by deconvolution methods, which require additional information, either cell counts or cellspecific reference transcriptomes. A review of the specific steps and analytic tools for RNA-seq data analysis has been recently published (16) . However, there remains controversy regarding the optimal methods for normalization of RNAseq data and for detecting differential expression. A few studies have examined these questions systematically (75) (76) (77) (78) (79) . Furthermore, selection of an analytic approach is also dependent on the experimental design; for example, not all available tools support inclusion of covariates. Caution is advised regarding the interpretation of results where the number of biologic replicates in an experiment is small or where transcripts are expressed at very low levels.
Reporting for RNA-Seq Experiments
We propose minimum elements to be reported for RNA-seq experiments (Table 3) , which extend the Minimal Information about Microarray Experiments (MIAME) guidelines (80) . These minimal reporting requirements are important because of the rapidly evolving landscape of methods and tools for the analysis of RNAseq data, the need to ensure RNA-seq data are both interpretable and reproducible, and the need to facilitate access to and integration of RNA-seq experiments across a spectrum of biologic and experimental conditions. Given the lack of consensus on the optimal methods for mapping versus assembling RNA-seq reads, normalizing RNA-seq data, and assessing for differential expression, we encourage investigators to repeat key analyses using more than one approach.
Data Analysis Bioinformatics
Sequencing technologies have improved to the point where the greatest barrier to obtaining scientific insights is more related to data storage, analysis, and interpretation than its generation (81) . The first critical component is an interdisciplinary team with expertise encompassing both the design and the use of specialized methods on sophisticated computational resources (82, 83) . Institutional infrastructure or external service providers that offer highperformance computing environments, including cloud computing and core facilities, are important to facilitate the generation and analysis of high-throughput sequence data. One significant advantage to these solutions is that they distribute costs over many users. In addition, these resources can help ensure high-quality data and results, as they are generated by devoted personnel who are more familiar with NGS approaches than occasional users. On the other hand, some analytic steps are best performed with feedback from those familiar with experimental design, rather than by pipelines that may overlook (89) . For samples passing initial QC, the next step involves quantification of levels of genes or transcripts. In most cases, reference gene or transcript files are obtained from Ensembl (90) or RefSeq (91) . The output of the quantification process is then used with an appropriate software package to measure differential expression and assess related QC. Regardless of program used, it is important to report false-discovery rate, adjusted P values and fold changes.
Data Sharing
To ensure that high-throughput sequence results are reproducible and that costly data can benefit all stakeholders, datasharing resources have grown significantly. Both raw data and results generated from projects sponsored by major funders are required to be deposited into publicly available databases. DNASeq data, including that of TOPMed, are deposited in dbGaP, along with individual-level phenotype and association results (50) . RNA-seq and other sequencing data are available in the Sequence Read Archive and can be discovered via the Gene Expression Omnibus (92).
Cell Type Heterogeneity
An important issue for consideration in many omics studies of the lung is cell heterogeneity. The lung is a complex organ comprising approximately forty resident cell types (93) , a growing number of cell subpopulations that are present either transiently during development or in adult lung (94) , as well as many types of inflammatory cells that infiltrate the airways and alveoli during periods of injury or disease. Thus, a signal measured by omics technologies in the whole lung can reflect a change in the pattern of expression of the molecules measured within a certain cell type, a change in the cellular composition of the lung, or both. There are three main approaches to deal with cellular heterogeneity. One approach is to perform statistical deconvolution of omic profiles by relying on cell-specific features from reference datasets. This approach has been used widely in peripheral blood profiling studies (95) and more recently on complex tissues (96), but it is highly dependent on known markers and difficult to implement for lung cell populations because of the limitations of appropriate reference datasets. The second approach is to isolate cell types on the basis of cell surface markers using flow cytometry or specific areas of the lung by laser capture microdissection (LCM). Although cell sorting is often used in immunological studies and has facilitated major contributions to the field (97), it is limited by the need for known cell markers and antibodies for cell populations of interest, as well as concerns that stress from cell sorting may affect gene expression patterns. LCM can be technically challenging on human lung tissue but has had some success in conjunction with sequencing technologies (98) . However, in most benign tissues, the resolution of LCM allows for enriching for a regional microenvironment but not for dissecting between different cell types.
Single-Cell Sequencing
The recently developed single-cell technologies provide the best solution to identification of all relevant cell populations, although technical limitations remain (99) (100) (101) . The reproducibility and success of such studies depend greatly on availability of high-quality human tissue, on cellular susceptibility to stress, and on the platforms used (102) . Despite these limitations, single-cell RNA-seq studies have shed light on lung cell population heterogeneity during lung development (103) and in lung diseases such as idiopathic pulmonary fibrosis (15) . The recent development of single-nucleus RNA-seq may address some of the issues 
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with tissue quality (104) . To address cellular heterogeneity in human lung disease, the field needs a "lung (disease) atlas," such as the one proposed by the human cell atlas (105) , a large collaborative set of studies that will systematically profile all cells in diseased and healthy human lungs. (107) . Because eQTLs may be cell specific, lung cell eQTL maps are needed to increase our understanding of lung-specific disease SNPs. Second, RNA-seq enables assessment of the relation of genetic variation with splicing events leading to alternative isoform expression (splice QTL). Finally, the association of genetic variation with transcripts induced by disease or specific stimuli (context-dependent eQTLs) can be investigated either in paired observational human studies or ex vivo in laboratory settings (Table 6 ). Because most respiratory diseases develop as a result from environmental exposures and genetic background, the study of inducible eQTLs may offer a good model to understand disease development by integrating genetic variation with induced gene expression.
Multiomics Integration
Using study-specific subsets of RNAseq data or external reference datasets such as the GTEx (Genotype-Tissue Expression project) consortium (108) allows for the ability to impute gene expression in large numbers of individuals for whom only genetic variant data are available (109) . These integrative approaches can expand (138) https: //bioconductor.org/packages/release/ bioc/html/DESeq2.html edgeR (139) http: //bioconductor.org/packages/release/ bioc/html/edgeR.html limma/voom (140) https: //bioconductor.org/packages/release/ bioc/html/limma.html PoissonSeq (141) https: //cran.r-project.org/web/packages/ PoissonSeq/index.html NOISeq (136) https: //bioconductor.org/packages/release/ bioc/html/NOISeq.html Sleuth (142) https: //pachterlab.github.io/sleuth/ Alternative splicing CuffDiff2 (143) http: //cole-trapnell-lab.github.io/cufflinks/ cuffdiff/ DEX-Seq (144) http: //bioconductor.org/packages/release/ bioc/html/DEXSeq.html DSG-Seq (145) http: //bioinfo.au.tsinghua.edu.cn/software/ DSGseq/ MISO (146) http: //genes.mit.edu/burgelab/miso/ rSeqDiff (147) http: //www-personal.umich.edu/zjianghui/ rseqdiff/ Leafcutter (148) https 
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the value of smaller sample sizes with transcript data to the larger datasets to identify gene expression correlated with phenotype (Table 6) . We anticipate that further integration of other omics data in bulk tissue or at the single-cell level, through efforts such as the Lung Map (110), will markedly increase our understanding of respiratory disease. The efficiency and speed of these types of analysis may be improved by the implementation of composite measures (111) in future research programs in respiratory medicine, particularly as the approach can be used for all types of omics analysis, including transcriptomics, proteomics, metabolomics, and epigenetics. Omics integration analysis has advanced considerably, and many machine learning methods are now being used, including Bayesian and network-based approaches (112) , and, more recently, deep learning and neural networks (113) .
Functional Validation
In functional studies, gene expression may also be used as outcome, either in vivo when human subjects or patients are exposed to an environmental stimulus or drugs or in human samples or animal models. Comparative analysis of humans and mouse models through RNA-seq may enable swift validation of downstream targets and provide insight in the validity of the animal model (114) . Additional sequencing methods such as DNA-Seq, Assay for Transposase-Accessible Chromatin sequencing (ATAC-Seq), and Chromatin Immunoprecipitation sequencing (ChIP-Seq) can identify functional regions affected by genetic variants. Gene editing techniques including Crispr-Cas9 that enable knockdown of genes or SNP-specific editing may be followed up by a readout on the effects of gene regulatory networks (115) ( Table 6 ).
Conclusions
With large efforts such as TOPMed and the U.K. Biobank, in addition to specific disease studies, there is an ever-increasing amount of sequencing data available for studies of respiratory disease, critical care, and sleep medicine. Because of the complex nature of these studies, it is critical to include researchers with multiple backgrounds at the outset of study design, including clinician-scientists and epidemiologists who can enroll and phenotype subjects; laboratory personnel with skills in biobanking, sample management, and high-throughput sequencing; bioinformaticians, statisticians, and computational biologists who can manage and analyze data; and molecular biologists who can conduct functional validation studies. All of these experts must collaborate to design studies, interpret data, and present results. This should not discourage new investigators from participating in omics studies, as each person can provide complementary expertise. Specific recommendations regarding study design, analysis, and follow-up (Box 1) should serve as guides for starting a new sequencing study or for the critical appraisal of a completed study. Genomics is a rapidly evolving field, and researchers must keep abreast of best practices. However, general principles of study design and data reporting are likely to remain valid in the future. n Table 6 . Selected examples of omics integration and using omics for functional validation studies
Technique Example
Context-dependent eQTLs Li and colleagues showed that cytokine production by peripheral blood mononuclear cells on stimulation depends on six specific SNPs (153) . One inducible cytokine QTL at the NAA35-GOLM1 locus markedly modulated interleukin-6 production in response to multiple pathogens and also showed association with susceptibility to candidemia. Imputed gene expression (PrediXcan) Ferreira and colleagues tested for associations between asthma and 17,190 genes found to have cis-and/or trans-eQTLs across 12 cell types relevant to asthma (154) . They confirmed 37 genes where the association was driven by eQTLs located in established risk loci for allergic disease and discovered 11 novel genetic associations. Gene knockdown Dixit and colleagues investigated the effect of gene knockdown by CRISPR/Cas9 on RNA-seq expression in human LPS stimulated bone marrow dendritic cells, a method they called Perturb-seq (155) . By analyzing the transcriptional consequences of perturbations of transcription factors in these cells, they were able to interpret the functional consequences of these transcription factors, as well as their interaction, uncovering their molecular mechanisms. 
AMERICAN THORACIC SOCIETY DOCUMENTS
4 Department of Pediatric Pulmonology and
